Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
Authors:
- M WirthMWM Wirth
- J ArmstrongJAJ Armstrong
- on behalf of the CASODEX Early Prostate Cancer Trialists' GroupOGon behalf of the CASODEX Early Prostate Cancer Trialists' Group
- 14 November 2006
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 10 (1) , 87-93
Abstract
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.ArticlKeywords
This publication has 18 references indexed in Scilit:
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU International, 2006
- Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 yearsScandinavian Journal of Urology and Nephrology, 2006
- Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programmeProstate Cancer and Prostatic Diseases, 2005
- Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARSJournal of Urology, 2004
- The psychological impact of cancer on patients’ partners and other key relativesEuropean Journal of Cancer, 2003
- Prostate cancer trends in the era of prostate-specific antigenUrologic Clinics of North America, 2002
- The bicalutamide Early Prostate Cancer ProgramUrologic Oncology: Seminars and Original Investigations, 2001
- BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUPJournal of Urology, 2000
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999